Automated insulin delivery device tested in newly diagnosed type 1 diabetes
Tests an automated insulin delivery device in young people newly diagnosed with type 1 diabetes.
Key facts
- Who runs it
- Stanford University
- Where
- Palo Alto, United StatesSee the site
- Trial code
- Registry title
- Early Automated Insulin Delivery (AID) Pilot for Newly Diagnosed T1D
- Status
- Not yet recruiting
- People taking part
- 16 people, planned
- Started
- Mar 2026
- Expected to end
- Mar 2031
- Type of study
- Interventional
- Treatments tested
- Tandem Automated Insulin Delivery System
- Record updated
- 30 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people recently diagnosed with type 1 diabetes who plan to receive care at Stanford Children's Pediatric Diabetes Clinic.
- Age
- From 2 Years to 26 Years.
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes diagnosed within the past 2 weeks.
Main reasons for not taking part
- No clinical diagnosis of type 1 diabetes
- Not following at Stanford Children's Pediatric Diabetes Clinic for clinical care
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Recent clinical diagnosis of type 1 diabetes within the past 2 weeks
- intent to follow at Stanford Children's Pediatric Diabetes Clinic for clinical care
Who cannot take part
- Does not have a clinical diagnosis of Type 1 diabetes
- Does not follow at Stanford Children's Pediatric Diabetes Clinic for clinical care
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 26 years old?
Where in United States
- Stanford Children'sPalo Alto, United StatesNot yet recruiting
About the trial
What the trial wants to find out
Type 1 diabetes is a common chronic medical condition among youth in the US that requires intensive glycemic management to prevent long-term morbidity and mortality. Current pediatric diabetes care in the US underutilizes automated insulin delivery (AID) systems, which are the best available tools for promoting tight glycemic control while reducing user burden. This proposal aims to support early and sustained use of AID systems by examining and optimizing conditions, evaluating glycemic outcomes, and identifying contextual facilitators and barriers of implementation.
The group in the trial
- Tandem Insulin PumpTreatment being tested
Participants will choose an automated Insulin Device either Tandem Mobi or Tandem X2. The participants will use the device to initiate early pump usage. Participants will use pump for approximately 2 Months, but may vary slightly upon individual insurances. The dose of insulin will vary between patient to patient based on food intake. Participants will complete surveys regarding their perspectives and experiences with the study intervention.
Treatment: Tandem Automated Insulin Delivery System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Early AID Pilot for Newly Diagnosed T1D
- Plain-language title
- Automated insulin delivery device tested in newly diagnosed type 1 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07501338, who can take part
- Record updated
- 30 March 2026